EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog

Mark J Vardanega iD, Tiffany Longo, Alex Aceino, Caleb K Alexander

Journal of Veterinary Internal Medicine · 04.05.2026 · 40 (3)

DOI: 10.1093/jvimsj/aalag116 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 18.06.2026. Verfasst von Mark J Vardanega und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ocean State Veterinary Specialists, East Greenwich, RI, United States. Hauptthemen laut MEDLINE: Dog Diseases, Carcinoma, Squamous Cell, Vulvar Neoplasms, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vulvovaginal squamous cell carcinoma (SCC) is an uncommon neoplasm in dogs. An 11-year-old female spayed German Shepherd dog presented with a history of excessive peri-vulvar grooming and a 3 cm × 3 cm irregular mass involving the vagina and vulva. Incisional biopsy confirmed a diagnosis of primary vulvovaginal SCC. Abdominal ultrasonography and thoracic radiographs indicated no evidence of systemic or regional metastasis. Surgical excision and adjuvant radiation therapy were declined, and the patient was treated with lapatinib, an orally administered dual tyrosine kinase inhibitor. Treatment resulted in a partial response within 1 month and complete resolution of the primary lesion within 3 months. No recurrence of the initial lesion was observed after 1 year of treatment despite development of perivulvar cutaneous lesions that were not associated with clinical signs. Lapatinib was well tolerated but did result in acute hepatic injury that was resolved using hepatoprotective antioxidant medication and intermittent treatment cessation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesCarcinoma, Squamous CellVulvar NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsVaginal NeoplasmsQuinazolinesAnimalsFemaleDogsLapatinib

Stichwörter der Autor:innen

dual tyrosine kinase inhibitorepidermal growth factor receptor inhibitorlapatinibvulvovaginal neoplasia

Substanzen

LapatinibAntineoplastic AgentsProtein Kinase InhibitorsQuinazolines

Autor:innen und Institutionen

  • Ocean State Veterinary Specialists, East Greenwich, RI, United States.
  • Antech Diagnostics, Middletown, CT, United States.

ORCID-Profile: Mark J Vardanega

Zitieren

APA

Vardanega, M. J., Longo, T., Aceino, A., & Alexander, C. K. (2026). Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog. Journal of Veterinary Internal Medicine, 40(3). https://doi.org/10.1093/jvimsj/aalag116

Vancouver

Vardanega MJ, Longo T, Aceino A, Alexander CK. Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog. Journal of Veterinary Internal Medicine. 2026;40(3). doi:10.1093/jvimsj/aalag116

BibTeX
@article{Vardanega2026,
  author = {Vardanega, Mark J and Longo, Tiffany and Aceino, Alex and Alexander, Caleb K},
  title = {Use of the dual tyrosine kinase inhibitor lapatinib for the treatment of vulvovaginal squamous cell carcinoma in a dog},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {3},
  doi = {10.1093/jvimsj/aalag116}
}
Kostenlos starten →